PNT2001 is a next-generation PSMA-targeted radioligand.
Patients diagnosed with prostate cancer can live many years, increasing the risk of latent radiation toxicity appearing from off-target delivery of radiation. The current generation of PSMA-targeted radioligands is therefore unlikely to move earlier in disease treatment or be paired with more powerful radioisotopes like Actinium-225, due to concerns related to potential radiation toxicity.
PNT2001 attempts to address these concerns through unique linker technology that enables increased tumor accumulation, potentially enabling lower doses of radioisotope, reducing off-target toxicity without affecting tumor kill.
PNT2001 is currently in the preclinical stage of development.